Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company positions itself to take advantage of Australian market

Changes to regulations in Australia have opened the door for cannabis breeders.
Picture of cannabis plant
The vertically integrated model aims to target multiple medicinal cannabis markets

The Hydroponics Company Ltd (ASX:THC) continues to build its capabilities to drive growth within the existing regulatory and clinical frameworks that exist in Australia.

Recruitment for the required skillsets to build the Australian business is underway.

Management is engaging personnel who can assist in research and development, growing and manufacturing, importation, clinical trials and promoting product demand.

There have also been management changes at the company with Dr Andrew Beehag, former head of Canndeo finishing in March 2018, and the experienced Steven Xu recently appointed as a director.

New engagements at an operational level and management changes will improve the group’s capabilities, driving growth within the existing regulatory and clinical frameworks that exist in Australia.

Well positioned to take advantage of changes in export rules

With more than 17 years of cannabis sativa breeding, variety selection and growth management, The Hydroponics Company is actively developing plant breeding technology.

This is aimed at multiple markets for high purity cannabidiol, a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.

The Hydroponics Company is well-positioned to take advantage of changes in export rules recently announced by the Federal Government.

This development resulted in the company’s shares increasing by circa 50% in January, and they touched a one-month intraday high of $1.12 less than a fortnight ago.

View full THC profile View Profile

The Hydroponics Company Timeline

Related Articles

February 02 2018
A first partnership agreement was signed with a South Korean company towards the end of 2017
August 17 2017
E-Therapeutics’ network-driven drug discovery platform looks at the broader interactions within disease mechanisms
Woman stroking face
October 03 2017
Its SkinBiotix cream was assessed for cellular toxicity

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use